N K Dieu Van

Learn More
AIMS To evaluate the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin or metformin in combination with sulphonylurea. METHODS In this 18-week, randomized, double-blind, placebo-controlled phase III study, patients (N = 676)(More)
  • 1